| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10059685 | HBV | ENSG00000158125.10 | protein_coding | XDH | No | No | 7498 | P47989 |
| TVIS10059683 | HBV | ENSG00000158125.10 | protein_coding | XDH | No | No | 7498 | P47989 |
| TVIS10059682 | HBV | ENSG00000158125.10 | protein_coding | XDH | No | No | 7498 | P47989 |
| TVIS10059684 | HBV | ENSG00000158125.10 | protein_coding | XDH | No | No | 7498 | P47989 |
| TVIS30050045 | HIV | ENSG00000158125.10 | protein_coding | XDH | No | No | 7498 | P47989 |
| TVIS20014252 | HPV | ENSG00000158125.10 | protein_coding | XDH | No | No | 7498 | P47989 |
| TVIS20066584 | HPV | ENSG00000158125.10 | protein_coding | XDH | No | No | 7498 | P47989 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | XDH |
|---|---|
| DrugBank ID | DB00437 |
| Drug Name | Allopurinol |
| Target ID | BE0002204 |
| UniProt ID | P47989 |
| Regulation Type | inhibitor |
| PubMed IDs | 11752352; 19584965; 19654053; 19436671; 20029618; 12184468; 5415686; 18409526; 19376361; 20046204; 16507884 |
| Citations | Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Suzuki I, Yamauchi T, Onuma M, Nozaki S: Allopurinol, an inhibitor of uric acid synthesis--can it be used for the treatment of metabolic syndrome and related disorders? Drugs Today (Barc). 2009 May;45(5):363-78. doi: 10.1358/dot.2009.45.5.1370460.@@Carro MD, Falkenstein E, Radke WJ, Klandorf H: Effects of allopurinol on uric acid concentrations, xanthine oxidoreductase activity and oxidative stress in broiler chickens. Comp Biochem Physiol C Toxicol Pharmacol. 2010 Jan;151(1):12-7. doi: 10.1016/j.cbpc.2009.07.010. Epub 2009 Aug 3.@@George J, Struthers AD: Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag. 2009;5(1):265-72. Epub 2009 Apr 8.@@Higgins P, Dawson J, Walters M: The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular disease. Cardiovasc Psychiatry Neurol. 2009;2009:282059. doi: 10.1155/2009/282059. Epub 2009 Nov 4.@@Dincer HE, Dincer AP, Levinson DJ: Asymptomatic hyperuricemia: to treat or not to treat. Cleve Clin J Med. 2002 Aug;69(8):594, 597, 600-2 passim.@@Kelley WN, Wyngaarden JB: Effects of allopurinol and oxipurinol on purine synthesis in cultured human cells. J Clin Invest. 1970 Mar;49(3):602-9.@@Okamoto K: [Inhibitors of xanthine oxidoreductase]. Nihon Rinsho. 2008 Apr;66(4):748-53.@@Taha MO, Simoes MJ, Noguerol EC, Mendonca FP, Pascoalick HM, Alves RA, Vivian ME, Morales FP, Campos AC, Magalhaes KG, Venerando PS, Tersariol IL, Monteiro HP, Oliveira-Junior IS, Jurkiewicz A, Caricati-Neto A: Effects of allopurinol on ischemia and reperfusion in rabbit livers. Transplant Proc. 2009 Apr;41(3):820-3. doi: 10.1016/j.transproceed.2009.02.051.@@Terkeltaub R: Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010 Jan;6(1):30-8. doi: 10.1038/nrrheum.2009.236.@@Pacher P, Nivorozhkin A, Szabo C: Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006 Mar;58(1):87-114. |
| Groups | Approved |
| Direct Classification | Pyrazolo[3,4-d]pyrimidines |
| SMILES | OC1=NC=NC2=C1C=NN2 |
| Pathways | |
| PharmGKB | PA448320 |
| ChEMBL | CHEMBL1467 |
